Article Versions Notes

Heshin-Bekenstein M, Ziv A, Toplak N, Lazauskas S, Kadishevich D, Ben-Nun Yaari E, Miller-Barmak A, Butbul Aviel Y, Saiag E, Pel S, et al. Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. Vaccines. 2023; 11(4):819. https://doi.org/10.3390/vaccines11040819

Heshin-Bekenstein, Merav, Amit Ziv, Natasa Toplak, Siman Lazauskas, Danielle Kadishevich, Efrat Ben-Nun Yaari, Adi Miller-Barmak, Yonatan Butbul Aviel, Esther Saiag, Sara Pel, and et al. 2023. "Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study" Vaccines 11, no. 4: 819. https://doi.org/10.3390/vaccines11040819

Heshin-Bekenstein, M., Ziv, A., Toplak, N., Lazauskas, S., Kadishevich, D., Ben-Nun Yaari, E., Miller-Barmak, A., Butbul Aviel, Y., Saiag, E., Pel, S., Elkayam, O., Uziel, Y., & Furer, V. (2023). Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. Vaccines, 11(4), 819. https://doi.org/10.3390/vaccines11040819